IHH Healthcare Berhad has received approval from the Securities and Exchange Board of India (SEBI) to proceed with its open offers for Fortis Healthcare Limited and Fortis Malar Hospitals Limited, according to an announcement made on October 3, 2025. The approval allows IHH to move forward with acquiring additional shares in both companies, potentially increasing its stake.

Open Offer Approval Received

IHH Healthcare Berhad (“IHH”) announced on October 3, 2025, that it has received approval from the Securities and Exchange Board of India to proceed with its open offers for Fortis Healthcare Limited (“Fortis”) and Fortis Malar Hospitals Limited (“Malar”).

Details of the Transaction

The transaction includes the following key components:

Background of the Transaction

This announcement refers to earlier announcements, including one made on December 17, 2018, regarding the proposed transactions.

Source: BSE

Trent Limited has issued a certificate regarding the dematerialization of securities for the quarter ended September 30, 2025. The certificate confirms compliance with regulatory requirements related to depositories and participants, ensuring that securities received for dematerialization have been duly processed and verified. This announcement reassures investors of Trent’s adherence to standard regulatory procedures.

Confirmation of Security Dematerialization

Trent Limited confirms the successful processing and verification of securities received for dematerialization for the quarter ending September 30, 2025. MUFG Intime India Private Limited, the Registrar and Share Transfer Agent, issued the certificate on October 3, 2025.

Regulatory Compliance

The certificate ensures adherence to the regulatory framework governing depositories and participants. It verifies that all securities received from depository participants during Q2 (July-September) have been accurately confirmed and processed. The listed securities have been duly verified and listed on the stock exchanges.

Implications for Investors

This certificate provides assurance to investors regarding the integrity and compliance of Trent Limited’s securities processing. The confirmation indicates that the company adheres to standard procedures for handling security certificates, ensuring investor confidence.

Source: BSE

The Reserve Bank of India (RBI) has imposed a penalty of ₹31.80 Lakhs on Indian Overseas Bank (IOB) due to certain non-compliances. The penalty was levied after an inspection by RBI related to the Supervisory Evaluation (ISE 2024). IOB has taken steps to strengthen internal processes to prevent future recurrences. The impact is considered non-material.

Penalty Imposed by RBI

Indian Overseas Bank (IOB) has received a communication from the Reserve Bank of India (RBI) regarding a monetary penalty. The penalty, amounting to ₹31.80 Lakhs, was imposed on September 30, 2025.

Reason for the Penalty

The penalty stems from the Statutory Inspection for Supervisory Evaluation (ISE 2024) conducted by RBI, referencing IOB’s financial position as of March 31, 2024. The penalty was imposed under provisions of Section 47A(1)(c) read with Section 46(4)(i) and 51(1) of the Banking Regulation Act, 1949.

Specific Non-Compliance

The non-compliance relates to the collection of loan-related charges in certain Priority Sector Lending (PSL) accounts. These accounts have sanctioned loan amounts up to ₹25,000.

Bank’s Response

IOB has taken preventive actions to further strengthen internal processes. This is aimed at preventing the recurrence of similar events in the future. The bank considers the impact of this regulatory action to be non-material to its present and future operations.

Source: BSE

Lupin has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States. This product is bioequivalent to Victoza and indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. The U.S. market had estimated annual sales of USD 350 million.

Liraglutide Injection Available

Lupin Limited has officially launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the U.S. This announcement was made on October 3, 2025.

Product Details and Indication

The newly launched Liraglutide Injection is bioequivalent to Victoza® Injection, 18 mg/3 mL (6 mg/mL). It is prescribed in addition to diet and exercise to help improve blood sugar control in adults and children aged 10 years and older who have type 2 diabetes.

Market Impact

According to data from August 2025, the U.S. market for Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza®), had an estimated annual sale of USD 350 million.

Executive Commentary

Spiro Gavaris, President – U.S. Generics, Lupin, stated, “We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”

Source: BSE

L&T Finance reported a strong business update for Q2FY26. Retailisation reached 98%. Retail disbursements are estimated at approximately ₹18,850 crores, a 25% Y-o-Y increase. The retail loan book is projected at around ₹1,04,500 crores, reflecting a 17% Y-o-Y growth. These figures demonstrate continued growth in the company’s retail segment.

Retailisation Momentum

L&T Finance reported significant progress in retailisation, achieving 98% in Q2FY26, up from 96% in Q2FY25. This indicates a strong shift towards retail lending.

Disbursement Growth

The company’s retail disbursements for Q2FY26 are estimated at approximately ₹18,850 crores, representing a growth of about 25% compared to the same period last year. Here’s a breakdown:

• Rural Business Finance: ₹6,310 crores (vs. ₹5,435 crores in Q2FY25)
• Farmer Finance: ₹1,650 crores (vs. ₹1,782 crores in Q2FY25)
• Urban Finance: ₹8,140 crores (vs. ₹6,285 crores in Q2FY25)
• SME Finance: ₹1,460 crores (vs. ₹1,244 crores in Q2FY25)
• Gold Finance: ₹980 crores
• Acquired Portfolio: ₹310 crores (vs. ₹346 crores in Q2FY25)

Retail Loan Book Expansion

The retail loan book at the end of Q2FY26 is estimated to be around ₹1,04,500 crores, which is about a 17% increase compared to the previous year.

Source: BSE

Tata Consumer Products confirms that all valid certificates of securities received for dematerialization have been mutilated and cancelled after due verification. The depository’s name has been substituted in the records as the registered owner. This announcement, dated October 3, 2025, pertains to the dematerialization process for the quarter ended September 30, 2025.

Dematerialization Certificate

Tata Consumer Products has issued a certificate confirming the dematerialization of securities. This confirmation follows the receipt of relevant documentation from MUFG Intime India Private Limited, the Registrar and Transfer Agent (RTA) for the company.

Details of Compliance

The company confirms that all certificates related to securities received for dematerialization have been duly processed. This includes mutilation and cancellation after thorough verification. The depository’s name has been officially substituted in the company’s records, reflecting the change in ownership.

This announcement is in accordance with certificate under regulation 74(5) for the quarter ended September 30, 2025. The certificates of securities which were dematerialized, are listed on BSE Limited, The National Stock Exchange of India Limited and The Calcutta Stock Exchange Limited.

Source: BSE

IHH Healthcare Berhad has received approval from the Securities and Exchange Board of India (SEBI) to proceed with its open offers for Fortis Healthcare Limited and Fortis Malar Hospitals Limited. The approval, detailed in a letter dated October 1, 2025, allows IHH to move forward with acquiring additional shares in both entities. The initial announcement regarding these offers was made on December 17, 2018.

Open Offer Approval

IHH Healthcare Berhad (IHH) has announced that it has received the green light from the Securities and Exchange Board of India (SEBI) to proceed with the mandatory open offers for Fortis Healthcare Limited and Fortis Malar Hospitals Limited. The approval was formalized via a letter from SEBI, dated October 1, 2025.

Details of the Transaction

The proposed transaction involves a subscription of 235,294,117 new equity shares in Fortis Healthcare, along with mandatory open offers to acquire additional shares. These offers include acquiring up to 197,025,660 shares in Fortis Healthcare, representing 26.10% of the expanded voting share capital, and up to 4,894,308 shares in Fortis Malar Hospitals, representing 26.11% of its voting share capital.

Background of the Offer

The initial announcement regarding these transactions was made on December 17, 2018. IHH has since been working towards obtaining all necessary regulatory approvals. The latest announcement confirms a significant step forward in the process.

Source: BSE

Tejas Networks has announced a change in the contact information for its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited. This update includes a new email address for investor communications, effective October 1, 2025. The announcement details the updated registered office address, email, website, telephone and fax numbers for investors.

Updated RTA Contact Details

Tejas Networks has announced important changes to the contact information of its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited. These changes are effective from October 1, 2025.

Key Changes

The primary update involves a new email address for all investor-related communications. Below are the comprehensive updated contact details:

Updated Contact Information

Registered Office: MUFG Intime India Private Limited, C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083

E-mail Address: [email protected]

Website Address: https://in.mpms.mufg.com/

Telephone: +91 810 811 8484

Fax: +91 22 4918 6060

Website Information

Further details regarding collection centers and branch locations can be found on the RTA’s website: https://web.in.mpms.mufg.com/office-network.html.

Source: BSE